Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor)

• Autors principals: Melinda Gooderham (Autor), Ronald Vender (Autor), Jeffrey Crowley (Autor), H. Chih-Ho Hong (Autor), Meghan Feely (Autor), Alyssa Garrelts (Autor), Kyoungah See (Autor), Bruce Konicek (Autor), Lawrence Green (Autor)
• Format: Llibre
• Publicat: Adis, Springer Healthcare, 2024-02-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Abstract Introduction When assessing the effect of a therapy for psoriasis (PsO), it is important to consider speed of response and cumulative response. However, responses among biologics may differ by body regions. This post hoc analysis compares speed of response and cumulative response for ixekiz...